Table 1 Baseline Sociodemographic and Clinical Characteristics (n= 112)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Characteristics | All (n=112 ) | Intervention group (n=57) | Control group (n= 55 ) | *P* |
| SexFemaleMale | 72 (64.3%)40 (35.7%) | 32 (56.1%)25 (43.9%) | 40 (72.7%)15 (27.3%) | 0.07 a |
| Age (years)MeanSD | 62.811.23 | 62.39.97 | 63.412.47 | 0.6  |
| Married/in a relationship YesNo | 89 (79.5%)23 (20.5%) | 48 (84.2%)9 (15.8%) | 41 (75.5%)14 (25.5%) | 0.21 a |
| EducationHighMiddleLowOther | 41 (36.6%)48 (42.9%)14 (12.5%) 9 (8.0%) | 25(43.9%)20(35.1%)7 (12.3%)5 (8.8%) | 16(29%)28(50.1%)7 (12.7%)4 (7.3%) | 0.33b |
| DiagnosisBreast cancerProstata cancerLung cancerGI cancer Gynological (uterine+ovarian) Pancreas | 32 (28.6%)12 (10.7%)32 (28.6%)22 (19.6%)8 (7.1%)6 (5.4%) | 16 (28.1%)9 (15.8%)15 (26.3%)11 (19.3%)3 (5.3%)3 (5.3%) | 16 (29.1%)3 (5.5%)17 (30.9%)11 (20.0)5 (9.1%)3 (5.5%) | 0.62 b |
| Anticancer treatmentCurativePalliativeUnknown | 36 (32.4%)75 (67.6%)1  | 19 (33.9%)37 (66.1%)1 | 17 (30.9%)38 (69.1%)0 | 0.73 a,c |
| Current treatment Chemotherapy (chemotherapy alone, chemotherapy+antibody, chemotherapy+ radiation)Targeted therapy(Immunotherapy, antibody)Other | 100 (89.3%)7 (6.3%)5 (4.5%) | 51 (89.5%)3 (5.3%)3 (5.3%) | 49 (89.1%)4 (7.3%)2 (3.6%) | 0.91 b |
| Attitude towards CAMDon´t knowAgainstNeutralPositiveVery positive | 2 (1.8%)3 (2.7%)19 (17.3%)55 (50%)31 (28.2%) | 1 (1.9%)2 (3.7%)9 (16.7%)22 (40.7%)20 (37.0%) | 1 (1.8%)1 (1.8%)10 (17.9%)33 (58.9%)11 (19.6% | 0.22b |
| Use of CAMYesNoDon´t know | 75 (68.2%)35 (31,8%)0 | 40 (74.1%)14 (25.9%)0 (0%) | 35 (62.5%)21 (37.5%)0 (0%) | 0.19a |

a Chi2-test (binære outcome)

b Fisher’s Exact test

c Based on patients with known treatment intention (i.e. n = 111)